Prelude Therapeutics Incorporated
NASDAQPrelude Therapeutics stock has surged 70% in a month. Now the lending market and options positioning are confirming the shift in sentiment. HC Wainwright's Robert Burns lit the fuse on April 27. He raised his price target from $5 to $8 — a 60% increase — while maintaining his Buy rating. That single move anchors the entire convergence now playing out across short interest, cost to…
Snapshot as of 6 May 2026
Prelude Therapeutics stock has surged 70% in a month. Now the lending market and options positioning are confirming the shift in sentiment. HC Wainwright's Robert Burns lit the fuse on April 27. He raised his price…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PRLD — free to start on ORTEX.
Sign up for free →Open PRLD on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live PRLD data →